Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
- Resource Type
- article
- Authors
- Thomas C.S. Martin; Lucas A. Hill; Michael E. Tang; Shannon M. Balcombe
- Source
- International Journal of Infectious Diseases, Vol 100, Iss , Pp 470-472 (2020)
- Subject
- Tenofovir alafenamide
HIV
Rifabutin
Co-administration
Infectious and parasitic diseases
RC109-216
- Language
- English
- ISSN
- 1201-9712
Objectives: Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to determine the efficacy of antiretroviral therapy regimens that include the co-administration of TAF and RFB. Methods: Persons with HIV (PWH) who received TAF–RFB co-administration for ≥1 month were identified retrospectively. The primary outcome was the maintenance of HIV viral load